« Running out of gas, revisited | Home | When will they learn? »

April 24, 2006

Scientific American on the FDA

John Rennie, SciAm‘s editor-in-chief, isn’t happy. But he is right:

What is completely wrong about the FDA’s position [on medical marijuana] is that in effect it continues to impede not just the medical use of marijuana but also medical research on marijuana, which could lead to superior therapies that don’t involve smoking or getting high at all.
Back in December 2004, SciAm published “The Brain’s Own Marijuana,” by Roger A. Nicoll and Bradley N. Alger (you can read the entire text here). The article’s deck tells the tale: “Research into natural chemicals that mimic marijuana’s effects in the brain could help explain—and suggest treatments for—pain, anxiety, eating disorders, phobias and other conditions.” The SA Perspectives that month argued with tight federal restrictions that limited the advance of that research:
… American biomedical researchers can more easily acquire and investigate cocaine. Marijuana is classified as a so-called Schedule 1 drug, alongside LSD and heroin. As such, it is defined as being potentially addictive and having no medical use, which under the circumstances becomes a self-fulfilling prophecy.
Any researcher attempting to study marijuana must obtain it through the National Institute on Drug Abuse (NIDA). The U.S. research crop, grown at a single facility, is regarded as less potent—and therefore less medicinally interesting—than the marijuana often easily available on the street. Thus, the legal supply is a poor vehicle for studying the approximately 60 cannabinoids that might have medical applications.
… The reasonable course is to make it easier for American researchers to at least examine marijuana for possible medical benefits. Great Britain, no slacker in the war on drugs, takes this approach: the government has authorized a pharmaceutical firm to grow different strains of marijuana for clinical trials.
This call for marijuana research is not a closet campaign for drug legalization—easing research barriers would not require that marijuana be reclassified, nor would it have any bearing on individual states’ decisions to approve limited use of medical marijuana. As a 1995 editorial in the Journal of the American Medical Association said, “We are not asking readers for immediate agreement with our affirmation that marijuana is medically useful, but we hope they will do more to encourage open and legal exploration of its potential.” After almost a decade of little progress, we reiterate that sentiment.
And now we have to reiterate it again. Medical marijuana is caught in a classic Catch-22 situation: It is banned because the federal government dismisses the evidence of therapeutic benefit as insufficient. But because marijuana is banned, scientists can’t easily gather more evidence to make the case. And new drugs based on marijuana are casualties of the same policies. Meanwhile, patients continue to suffer despite strong evidence that work in this area could lead to better medicines.
How does this seem like a good arrangement? Seriously, what are the feds smoking?

Posted by Stephen at 8:00 PM in Drugs | Permalink | TrackBack (0)

Trackback Pings

TrackBack URL for this entry: